Resolution Therapeutics extends inflammatory and fibrotic disease pipeline with in vivo Regenerative Macrophage Therapy
- Material Transfer Agreements provide access to leading lipid nanoparticle formulations to validate delivery of its proprietary payloads and accelerate development of in vivo Regenerative Macrophage Therapy
- Development programme complements Company’s autologous engineered Regenerative Macrophage Therapy, RTX001, in Ph 1/2 clinical development
- Together, programmes aim to broaden patient population able to benefit from Regenerative Macrophage Therapy
Edinburgh and London, UK, 17 June 2026 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announced the execution of Material Transfer Agreements with independent, best-in-class lipid nanoparticle (LNP) technology providers. Under the agreements, Resolution will conduct systematic assessments of LNP formulations for the engineering of the myeloid compartment in vivo, with preliminary results expected later this year.
